Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2008;51:1109-1114
Published online before print February 7, 2008, doi: 10.1161/HYPERTENSIONAHA.107.107474
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
51/4/1109    most recent
HYPERTENSIONAHA.107.107474v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gerdts, E.
Right arrow Articles by Devereux, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gerdts, E.
Right arrow Articles by Devereux, R. B.
Related Collections
Right arrow Hypertrophy
Right arrow Clinical Studies
Right arrow Echocardiography

(Hypertension. 2008;51:1109.)
© 2008 American Heart Association, Inc.


Go Red Original Articles

Gender Differences in Left Ventricular Structure and Function During Antihypertensive Treatment

The Losartan Intervention for Endpoint Reduction in Hypertension Study

Eva Gerdts; Peter M. Okin; Giovanni de Simone; Dana Cramariuc; Kristian Wachtell; Kurt Boman; Richard B. Devereux

From the Institute of Medicine (E.G., D.C.), University of Bergen, Bergen, Norway; Department of Heart Disease (E.G., D.C.), Haukeland University Hospital, Bergen, Norway; Department of Medicine (P.M.O., R.B.D.), Weill Medical College of Cornell University, New York, NY; Department of Clinical and Experimental Medicine (G.d.S.), Federico II University Hospital, Naples, Italy; Heart Center (K.W.), Rigshospitalet, Copenhagen, Denmark; and the Department of Medicine (K.B.), Skellefteå Hospital and Umeå University, Skellefteå, Sweden.

Correspondence to Eva Gerdts, Institute of Medicine, University of Bergen, Haukeland University Hospital, N-5021 Bergen, Norway. E-mail gerdtsev{at}online.no

In hypertensive patients with left ventricular hypertrophy, antihypertensive treatment induces changes in left ventricular structure and function. However, less is known about gender differences in this response. Baseline and annual echocardiograms until the end of study or a primary end point occurred were assessed in 863 hypertensive patients with electrocardiographic left ventricular hypertrophy aged 55 to 80 years (mean: 66 years) during 4.8 years of randomized losartan- or atenolol-based treatment in the Losartan Intervention for Endpoint Reduction in Hypertension Echocardiography substudy. Left ventricular hypertrophy was diagnosed as left ventricular mass divided by height2.7 ≥46.7 g/m2.7 and 49.2 g/m2.7 in women and men, respectively, and systolic function as ejection fraction and stress-corrected midwall fractional shortening. Women included more patients with obesity, isolated systolic hypertension, and mitral regurgitation (all P<0.01). Ejection fraction, stress-corrected midwall shortening, and prevalence of left ventricular hypertrophy were higher in women at baseline and at the end of study (all P<0.01). In particular, more women had residual eccentric hypertrophy (47% versus 32%; P<0.01) in spite of similar in-treatment reduction in mean blood pressure. In logistic regression, left ventricular hypertrophy at study end was more common in women (odds ratio: 1.61; 95% CI: 1.16 to 2.26; P<0.01) independent of other significant covariates. In linear regression analyses, female gender also predicted 2% higher mean in-treatment ejection fraction and 2% higher mean stress-corrected midwall shortening (both β=0.07; P<0.01). Hypertensive women in this study retained higher left ventricular ejection fraction and stress-corrected midwall shortening in spite of less hypertrophy regression during long-term antihypertensive treatment.


Key Words: gender • hypertension • systolic function • left ventricular hypertrophy • hypertrophy regression




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
L. Zelarayan, A. Renger, C. Noack, M.-P. Zafiriou, C. Gehrke, R. van der Nagel, R. Dietz, L. de Windt, and M. W. Bergmann
NF-{kappa}B activation is required for adaptive cardiac hypertrophy
Cardiovasc Res, December 1, 2009; 84(3): 416 - 424.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
E. Gerdts
Left ventricular structure in different types of chronic pressure overload
Eur. Heart J. Suppl., July 1, 2008; 10(suppl_E): E23 - E30.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
E. Agabiti-Rosei and M. Salvetti
Gender Differences in the Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy
Hypertension, July 1, 2008; 52(1): 59 - 60.
[Full Text] [PDF]


Home page
HypertensionHome page
I. Os, R. B. Devereux, and P. M. Okin
Response to Gender Differences in Left Ventricular Hypertrophy Regression
Hypertension, June 1, 2008; 51(6): e59 - e59.
[Full Text] [PDF]